How the World's Top 10 Medical Centers Drive Innovation and Translation: A Blueprint for Global Healthcare Transformation

For the vast majority of medical institutions in China, innovation and translation appear to be an insurmountable challenge, evenWith policies, funding, platforms, and talent., yet in practice, they still feel unable to meet the demands, and the ultimate benefits realized are far from ideal, with most still engaged in“Loss-Making Business”。

But the global landscape presents a different picture.

According to the latest data,Mayo ClinicTo date, 140,000 medical innovation achievements have been successfully incubated, with an additional 12,000 innovative technologies currently in the research and translation stages;Cleveland ClinicIn 2021, 92 innovative projects were successfully commercialized, attracting over $1.3 billion in investment;Johns Hopkins HospitalIn 2021, a total of 444 invention disclosures were processed, 166 new patents were granted, and the number of startups reached 174;The University of Tokyo HospitalIn 2021, it achieved over $35 million in research income, with its innovation division having achieved “financial self-sufficiency”.......

This is no easy feat. Even for these world-leading medical centers, achieving success in innovation and translation has undoubtedly required a long journey and many right decisions.

So, what exactly did they do right? Can domestic medical institutions replicate their success? To answer these questions,VBOrange BureauSystematically reviewedInnovation Translation Pathways of the Top 10 Global Medical Centers.

The answer is often unique.

Through an analysis of these ten leading medical institutions, we have found that they have almost all adopted “Clinical-Research-Education”this incubation model. In fact, this “Universal Formula”has been validated as the most efficient operational model for current healthcare institutions to focus on innovation and translation.

This is certainly for a reason, because"Clinical practice, scientific research, and education are inherently interconnected."First, a large volume of clinical cases can guide and validate scientific research. Second, new research findings can, in turn, provide better solutions for clinical practice. Finally, education serves to closely integrate these two domains, continuously injecting fresh talent into both the clinical and research fields.

But this is conditional.

The first point is awareness, meaning that physicians must have the willingness to engage in scientific research.Among these world-leading medical centers, most have established dedicated research departments or research centers, where doctors devote 90% of their efforts to their own research and are minimally involved in clinical practice.Mayo Clinicas an example, it currently has a total of57 research centers and more than 3,800 specialized researchers, with annual investments in medical innovation research reaching as high asHundreds of millions of dollars, which has driven the generation of thousands of scientific research achievements each year.

In China, however, the situation is reversed: most physicians are more focused on clinical practice, with various performance metrics also being clinically oriented. As a result, enthusiasm for participating in scientific research is generally low among doctors, and only a small minority are truly willing to transition from clinical work to laboratory research.

The second point is capability, meaning that doctors can meet the "objective conditions" required for conducting scientific research.For physicians, the primary challenge in dedicating themselves to scientific research is overcoming time constraints. Since most physicians who engage in research are key clinical practitioners, it is difficult for them to carve out time for research activities without adequate institutional support and flexibility.

However, time alone is not enough; sufficient capability is also required.Scientific research is, in essence, an interdisciplinary process that integrates multiple fields; beyond medical expertise, it also requires a certain level of engineering literacy.In the U.S. physician training system, doctors must first complete a four-year undergraduate program, during which they can acquire extensive knowledge in engineering-related fields. Only after this stage do they enter medical school to study clinical medicine, and finally undertake rotational clerkships across various hospital departments.

In contrast, the domestic training model is quite different. Medical students receive medical education from the very beginning; therefore, without prior accumulation or systematic post-hoc learning, physicians possess an extremely limited understanding of engineering disciplines. This deficiency makes it difficult for many doctors in China to engage in scientific research.

The third point is motivation, meaning that physicians can derive satisfaction from scientific research. The sustainable development of any endeavor requires a positive incentive mechanism, and this is particularly true for scientific research., because it is an endeavor involving only a very small number of participants, if these individuals fail to receive due returns in the process, this will not only cause the original participants to “turn away,” but also deter potential newcomers from getting involved.

But to achieve returns in scientific research, besides havingA Problem-Solving Incubation Platform, and also haveA Reasonable Incentive Mechanism. Because scientific research is a relatively complex endeavor involving numerous elements, some of which are within physicians’ capabilities while others exceed them, healthcare institutions should establish such a platform to address the challenges that physicians cannot resolve on their own in their research activities, thereby effectively ensuring conversion rates.

With high conversion rates, results are inevitable; subsequently, rational allocation is required, which necessitates a sound incentive mechanism.Ensure that every stage of participation in scientific research receives its due returns.

Therefore,"Clinical Practice-Research-Education"This innovative framework merely provides medical centers with a “universal formula.” To apply it rationally and successfully navigate this pathway, medical centers must devote greater attention to the nuances of innovation and translation, thereby addressing the root causes of existing challenges.

There is often only one answer, but the paths to reach it are diverse.

Among these ten leading global medical institutions, each has provided distinctly different answers on how to transform scientists into entrepreneurs and convert research findings into marketable products, based on their respective circumstances.

To advance medical innovation and commercialization, Mayo Clinic has establishedBusiness Development Department, positioning it as equivalent to a technology transfer center; however, unlike traditional technology transfer centers, it primarily serves as a multidisciplinary communication platform that helps research teams stay abreast of the latest medical technologies and gain insights into evolving market trends.

In addition, the Business Development Department also serves as a bridge between the research team and the market, primarily embodied in its specially established “right-hand men,” namelyMayo Clinic VenturesandCorporate Development Department。Mayo Clinic Venture CapitalIts core competencies are primarily reflected in the ability to evaluate and protect intellectual property, fully leverage technical funding, and execute and manage licensing agreements, ultimately driving the establishment of startups;Enterprise Development Departmentis primarily responsible for strategic transactions at the Mayo Clinic, including but not limited to the evaluation, analysis, and development of new business opportunities, mergers and acquisitions, and equity investments.

Cleveland Clinic boasts a unique portfolio in the field of medical research, perfectlyAchieved "Translational Medicine" from basic medical research to clinical application and then to commercial product development.. First is basic medical research, primarily conducted byLerner InstituteTo date, more than 1,200 researchers are working at the Lerner Research Institute, jointly seeking new cures for diseases. This is followed by clinical medical applications: Cleveland Clinic boasts a substantial pool of physician-scientists who can accurately identify current clinical needs and provide constructive recommendations.

Finally, commercial translation,Cleveland Clinic Established the Cleveland Clinic Innovations, the department operates a total of four incubators, namelyMedical Information Technology, Medical Devices, Diagnostics and Therapeutics, and Delivery Solutions. In addition, the Innovation Department also “engages” in investment; according to information disclosed on its official website, its main investment areas includeMedical Devices, Diagnostics and Therapeutics, System Software, and Biopharmaceuticals, attracting over$1.3 billioninvestment, bringing investors nearly$90 millionbenefits.

Massachusetts General Hospital has long been committed to bridging innovative science and advanced clinical medicine, thereby forging a robust “self-digestion” capability in innovation and translation, namelyThe complete workflow from basic research to clinical research and then to translational research.

First, Basic Research, Massachusetts General Hospital closely connects scientists with clinicians to realize the transition from “bench to bedside”;Next is the clinical research,This phase primarily involves testing promising candidate therapies, diagnostics, and devices, as well as recruiting subjects for clinical trials.

Finally, there is the crucial translational research.Massachusetts General Hospital has established a dynamic process comprising four key components: first, launching the “Bridging Academia and Industry” training program to actively orient scientists toward the market; second, establishing a Translational Research Center to facilitate initial clinical trials in collaboration with industry partners; third, creating a “think tank” that brings together participants across the innovation ecosystem to brainstorm and share insights; and fourth, introducing a new partnership model to streamline contract negotiations and Institutional Review Board (IRB) approvals.

The research translation pathway at Toronto General Hospital can be broken down into the following 10 steps:1. Research, triggering new discoveries and inventions through observations and experiments in research activities;2. Intellectual Property Disclosure, marking the beginning of the technology transfer process;Third, Assessment, review invention disclosures through patent searches, and then analyze their market and competing technologies to assess the commercialization potential of the inventions;Fourth, Intellectual Property Protection, protect inventions with commercial potential through patents, and safeguard those with weaker commercial potential through other forms of intellectual property protection;5. Marketing, promote the invention to companies that may be interested in its commercialization.

6. Select the Optimal Licensee, license the invention to the company with the greatest commitment and capability to bring the technology to market;7. Licensing, after negotiating with the licensee, the Technology Transfer Office executes the license agreement;8. Commercialization, the Technology Transfer Office provides support to innovative projects in regulatory approval, sales and marketing, support, training, and other activities;9. Redistribution of Interests, after receiving royalties from the licensee, the hospital distributes them equally between the inventors and the hospital in accordance with its policies to fund additional research and operational activities;10. Reinvestment, reinvest the funds returned to hospitals to jointly promote the inventions and innovations of the next generation of researchers and innovators.

To create a complete ecological closed loop from the “laboratory” to the “market,” Johns Hopkins Hospital has specifically established an industry-leading venture capital firm and the university’s Intellectual Property Management Center—Johns Hopkins Technology Ventures, guided primarily by the core values of the Johns Hopkins University School of Medicine, it maximizes Johns Hopkins University’s outstanding research capabilities through three major departments.

Its efforts are mainly focused on three areas:1. Technology Transfer Team, the department provides “one-stop” commercialization services for licenses, patents, and technologies to researchers at the medical school;2. Corporate Cooperation Office, by establishing partnerships to provide industry partners with cohesive end-to-end services, and further bringing inventions and discoveries from Johns Hopkins Laboratory to market through strategic collaborations;Third, the FastForward Innovation Incubation Center, to support the development of startups both within and outside universities by providing early-stage financing to promising ventures.

As Europe's largest healthcare institution, Charité Hospital primarily relies on innovation and translation for itsBerlin Institute of Health, jointly established by the German Federal Ministry of Education and Research and the State of Berlin, it has built an internal ecosystem that fosters a systems-level understanding of health and disease and promotes a cultural shift in biomedical research.

Specifically, the Berlin Institute of Health primarily focuses its efforts across five dimensions,First is the invention disclosure, ensuring that scientists' achievements receive a certain level of attention;Secondly, to provide advice on intellectual property-related issues,Help scientists better safeguard their rights and interests;Then, providing consultation on grant applications., continue to promote scientific research;Furthermore, guiding scientists in the process of establishing spin-off companies,To help them make fewer mistakes, or even no mistakes at all;Finally, it supports the development of scientists in the field of contract management., helping the company achieve healthy growth in the future.

Behind Singapore General Hospital lies a powerful “helper”—one of the world’s largest academic medical centers,Singapore Health Group. The group has under its umbrellaFour public hospitals, three community hospitals, five national specialty centers, and eight general clinics,Dedicated to leveraging its scientific research, technology, and growing expertise to advance fundamental science, medical, and biological research, thereby creating a sustainable and publicly accessible high-quality healthcare system.

Under this “group model,” Singapore General Hospital is no longer “going it alone” and has received greater support in multiple areas of innovation and translation. The first is “Cross-Border”, the establishment of multidisciplinary, cross-sector collaboration platforms to promote the development of translational medicine; secondly, “VBInsight,” which means pooling resources from multiple parties to provide multi-dimensional services in scientific research and translational practice; finally, “Labor-saving”, providing specialized services for the commercialization of innovative projects.

In medical innovation and translation,Lausanne University HospitalParticular emphasis is placed on integration with market-oriented mechanisms; it is precisely for this reason that a dedicatedPACTT (Technology Transfer Office)this functional department.

To achieve differentiated innovation, after evaluating the project, PACTT has mapped out two commercialization pathways for scientists:One is to seek commercial partners for it, and the other is to encourage scientists to start their own businesses.Regardless of the path chosen, PACTT’s primary role is to provide scientists with extensive, professional business advice, thereby bridging their commercial knowledge gaps. Secondly, it aims to alleviate their financial burdens, primarily by securing additional project grants and attracting investment institutions. Finally, it ensures a fair and equitable distribution of profits, guaranteeing that every participant benefits.

It is reported that the Israeli government allocates approximately 8% of its total annual fiscal budget to healthcare. In addition, the government has implemented a series of measures to promote the flourishing development of the medical sector, including establishing the National Innovation Authority, enacting the “Angel Law,” and launching the “National Technological Incubator Program.” Sheba Medical Center has significantly benefited from these initiatives.

On one hand, it is reflected in digital health strategic policies, which are dedicated to leveraging communication technologies to improve healthcare services through robust innovation capabilities and advanced technological development; on the other hand, it involves building a bridge between hospitals and the market throughARC Partner Innovation Program, Sheba Medical Center has joined this innovative initiative alongside many other hospitals in Israel and around the world, primarilyBy regularly meeting with hospital medical teams to gather physicians’ insights and needs and to exchange updates on the latest projects and outcomes, we aim to foster collaboration between hospitals, startups, and large corporations in information sharing and other areas.

To promote innovation and translation,The University of Tokyo HospitalDivide scientific research into three levels:First is basic research, mainly comprising three core stages: transforming ideas into projects, third-party evaluation, and ethical review;Second, interdisciplinary research, to build a bridge between medicine and engineering, the Hospital of the University of Tokyo has established a Medical-Engineering Collaboration Department. Its core mission is to foster close ties with key disciplines such as pharmacy, informatics, and chemistry, jointly promoting the clinical translation of research achievements to effectively address clinical challenges.

Third, Translational Research, the University of Tokyo Hospital established “22nd Century Medical Center", today, the center has developed11 Donor Departments and 3 Social Collaboration Departments. The Fundraising Department primarily facilitates the commercialization of scientific research outcomes by securing corporate sponsorships; meanwhile, the Social Collaboration Department mainly fosters partnerships between innovators and clinical professionals to jointly conduct research and medical evaluations, while also assisting in the development and operation of clinical databases to perform systematic analyses supporting the commercialization of scientific research.

In recent years, enthusiasm for medical innovation and translation has reached unprecedented heights in China. As the source of innovation, medical centers are inevitably required to shoulder greater responsibilities, yet the immediate challenges remain evident.

First is the issue of physician autonomy.Due to the misalignment of “performance appraisal,” most physicians in China continue to focus primarily on clinical work, leaving them with little time to devote to scientific research.

Secondly, there is a lack of original innovation capability.. Given that the majority of physicians in China have long operated within a closed, hospital-centric environment, their accumulation of engineering-related knowledge is quite limited, and they lack a comprehensive understanding of the market. Consequently, innovative achievements that are truly applicable to the market remain “negligible.”

Then there is the lack of clarity in the commercialization path.Medical innovation and translation are extremely complex. In addition to the proactive involvement and efforts of physicians, corresponding policies, platforms, and resources must also keep pace. However, to date, a comprehensive system has yet to be established within China’s healthcare institutions, causing many innovative achievements to fail to transition out of the laboratory and largely fall into the “valley of death” in innovation.

Finally, there is ambiguity in the allocation of intellectual property rights.In 2002, China’s “Several Provisions on the Management of Intellectual Property Rights in Research Outcomes of National Scientific Research Programs” explicitly stipulated that intellectual property rights arising from research projects funded by fiscal appropriations would shift from state ownership to ownership by the institutions undertaking the projects. However, this policy failed to achieve its intended effect, as decision-makers along the technology transfer chain did not truly understand the commercialization of scientific and technological achievements, and the overarching mindset of the system did not evolve with the times. Consequently, stakeholders involved in innovation and technology transfer did not receive the returns they deserved.

What best practices can we distill from the innovation and translation pathways of the top 10 medical centers globally?

First, allow a subset of physicians to transition out of clinical practice.Among these ten medical centers, it is evident that each has established its own medical department or research institute, with the aim of allowing a subset of physicians to fully disengage from clinical duties and devote themselves entirely to scientific research.

Second, “screening” for innovation capability.Resources are limited and should be allocated where they matter most. Therefore, when faced with thousands of innovative projects, medical centers should establish a comprehensive “evaluation mechanism” to truly identify those projects with strong innovation potential and practical application value, and then allocate corresponding resources accordingly.

Third, establish an innovation incubation platform with “composite capabilities.”Among these ten medical centers, nearly all have established their own translational platforms. Although named differently, these platforms serve largely similar purposes: to address the various challenges physicians face during innovation and translation, ultimately facilitating the successful market entry of their innovative projects.

However, this process involves numerous elements, requiring translation platforms to possess multifaceted capabilities and diverse resources. Taking the critical element of funding as an example, on one hand, translation platforms must have the ability to evaluate projects from a commercialization perspective; on the other hand, they need to connect with investment institutions active in the market, categorize them based on their characteristics, and thereby achieve precise matching.

Fourth, ensure that every participant receives a return.. Prior to 1978, the commercialization rate of biotechnology achievements in the United States was only 5%, but by the early 1990s, it had rapidly climbed to 80%. The “trigger” for this transformation was what Americans take pride in:"The Bayh-Dole Act", and itThe primary focus is on addressing the issue of benefit distribution in the process of translating scientific research achievements into practical applications.

Therefore, we have observed that many medical centers have established dedicated profit-sharing systems or entities. WithCleveland Clinicas an example, it has specifically establishedConflict of Interest Association, with the aim of making benefit distribution more rational and transparent; for example,Toronto General Hospital, it has established a benefit distribution policy, allocating proceeds to inventors and the hospital in accordance with this policy. The hospital’s share is then used to fund new innovation projects, creating a virtuous and sustainable cycle of innovation.

In addition to these methodologies, it is important to emphasize that the ten medical centers did not achieve innovation and translation “overnight.” They all underwent a prolonged period of “trial and error” before making breakthroughs in medical innovation and translation. Therefore, when confronting the complex challenge of medical innovation and translation, domestic medical centers, besidesBeyond continuously refining oneself, one must also wait and undergo constant validation over time.